Zacks1d agobearish
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss EstimatesCRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
News
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
292last 24h
1156last 7d
241🟢 bullish (7d)
105🔴 bearish (7d)
87publishers